We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 5 for:    bld-0409

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04939467
Recruitment Status : Completed
First Posted : June 25, 2021
Last Update Posted : April 15, 2022
Sponsor:
Information provided by (Responsible Party):
Blade Therapeutics

Brief Summary:
A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone when Administered Concurrently in Healthy Volunteers

Condition or disease Intervention/treatment Phase
Drug Drug Interaction Drug: Pirfenidone 267 mg Oral Tablet Drug: Nintedanib 150 mg Oral Capsule Drug: BLD-0409 750 mg Oral Tablet Phase 1

Detailed Description:
This is a single-center, open-label study designed to determine the effect of BLD-0409 on the PK of nintedanib and pirfenidone, all at steady state, and to evaluate the safety and tolerability of BLD-0409 administered with either nintedanib or pirfenidone in healthy adult volunteers

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone When Administered Concurrently in Healthy Volunteers
Actual Study Start Date : October 15, 2021
Actual Primary Completion Date : December 16, 2021
Actual Study Completion Date : April 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Pirfenidone & BLD-0409
Following an overnight fast, subjects will be administered IP in a fixed sequence.
Drug: Pirfenidone 267 mg Oral Tablet
Fixed sequence use of active product, TID

Drug: BLD-0409 750 mg Oral Tablet
Fixed sequence use of active product, QD

Experimental: Nintedanib & BLD-0409
Following an overnight fast, subjects will be administered IP in a fixed sequence.
Drug: Nintedanib 150 mg Oral Capsule
Fixed sequence use of active product, BID

Drug: BLD-0409 750 mg Oral Tablet
Fixed sequence use of active product, QD




Primary Outcome Measures :
  1. Maximum observed drug concentration (Cmax) [ Time Frame: Up to 18 days ]
    Estimated from plasma concentration

  2. Time of the maximum drug concentration (Tmax) [ Time Frame: Up to 18 days ]
    Estimated from plasma concentration

  3. Area under the drug concentration-time curve (AUC) as follows: Pirfenidone - AUC0-8 (Arm 1); Nintedanib - AUC0-12 (Arm 2); BLD-0409 - AUC0-24 (both arms). [ Time Frame: Up to 18 days ]
    Estimated from plasma concentration


Secondary Outcome Measures :
  1. Incidence, nature and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 18 days ]
    Safety and tolerability will be assessed based on the incidence, nature and severity of TEAEs and SAEs, and changes in safety laboratories, vitals and ECGs



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male and female participants 18-55 years of age (inclusive) at the time of signing the ICF.
  2. Participants must be in good general health, in the opinion of the investigator, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening, and/or before administration of the initial dose of IP.
  3. Participants must have clinical laboratory values within normal ranges or < 1.2 times upper limit of normal (ULN) as specified by the testing laboratory, unless deemed not clinically significant (NCS) by the investigator.
  4. Body mass index (BMI) 18 to ≤ 30 kg/m2.
  5. Female participants must use double barrier contraception and refrain from oocyte donation from at least 28 days prior to Screening and for 90 days after last dose of IP.
  6. Male participants and female partners of male participants must agree to use highly effective, double barrier contraception and refrain from sperm donation from first dose of IP and for 90 days after last dose of IP.
  7. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. Females not of childbearing potential must be surgically infertile or post-menopausal (defined as cessation of regular menstrual periods for at least 12 months), confirmed by follicle-stimulating hormone (FSH) level >40 mIU/mL at Screening.
  8. Participants must provide signed informed consent prior to study entry and have the ability and willingness to attend and comply with the necessary visits at the study site.

Exclusion Criteria:

  1. Recent (less than 6 weeks) wound, or presence of an ongoing non-healing skin wound.
  2. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol.
  3. Known cardiac disease.
  4. Active malignancy and/or history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low grade cervical intraepithelial neoplasia.
  5. Serious local or systemic infection within 1 month of Screening requiring antibiotic treatment or history of recurrent infections.
  6. Any acute illness within 30 days prior to Day 1.
  7. Surgery, bone fracture or major musculoskeletal injury within the past 3 months prior to the first IP administration determined by the investigator to be clinically relevant.
  8. Positive for human immunodeficiency virus (HIV) antibody or antigen.
  9. Positive hepatitis C virus (HCV) antibody or positive hepatitis B surface antigen (HBsAg).
  10. Systolic blood pressure (BP) > 150 mmHg or < 90 mmHg or diastolic BP >90 mmHg or <50 mmHg at Screening with one repeat allowed per the investigator's discretion at Screening and Day -1.
  11. Heart rate < 40 beats per minute (bpm) or > 100 bpm at Screening.
  12. Prolonged QT interval corrected by Fridericia's formula (QTcF) (>450 ms for males and >470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the investigator.
  13. All prescription and over-the-counter medications (including herbal medications), except for contraceptives, are prohibited within 7 days prior to the first IP administration and throughout the entire duration of the study.
  14. All vaccines within 14 days prior to first IP administration and throughout the entire duration of the study.
  15. Administration of investigational product in another study within 30 days prior to the first IP administration (except BLD-0409), or five half-lives, whichever is longer.
  16. Significant weight loss or gain between Screening and first IP administration.
  17. Blood donation or significant blood loss within 60 days prior to the first IP administration.
  18. Plasma donation within 7 days prior to the first IP administration.
  19. Females who are pregnant or breastfeeding.
  20. Diets that could alter metabolism (i.e., high protein, Slim Fast®, Nutrisystem®, etc.) within 7 days prior first IP administration.
  21. History or presence of alcohol or drug abuse within the 1 year prior to the first IP administration, and unwillingness to be totally abstinent during the treatment period.
  22. Positive urine drug screen/alcohol breath test at Day -1 (admission). Repeat urine drug screens will be permitted for suspected false positive results.
  23. Intake of alcohol or caffeine-containing products from 48 hours before first IP administration through the EOS visit.
  24. Active smokers and users of nicotine-containing products. Note, participants must discontinue smoking/use of nicotine-containing products from 48 hours before first IP administration through the EOS visit.
  25. Failure to satisfy the investigator of fitness to participate for any other reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04939467


Locations
Layout table for location information
United States, Florida
Advanced Pharma
Miami, Florida, United States, 33147
Sponsors and Collaborators
Blade Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Kimberly S Cruz, MD Advanced Pharma CR, LLC
Layout table for additonal information
Responsible Party: Blade Therapeutics
ClinicalTrials.gov Identifier: NCT04939467    
Other Study ID Numbers: B-0409-104
First Posted: June 25, 2021    Key Record Dates
Last Update Posted: April 15, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pirfenidone
Nintedanib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents